Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 53.65M P/E - EPS this Y -2.50% Ern Qtrly Grth -
Income -65.41M Forward P/E -3.63 EPS next Y 13.20% 50D Avg Chg -5.00%
Sales - PEG -1.39 EPS past 5Y - 200D Avg Chg 66.00%
Dividend N/A Price/Book 14.83 EPS next 5Y 15.00% 52W High Chg -23.00%
Recommedations 1.50 Quick Ratio 29.08 Shares Outstanding 38.87M 52W Low Chg 464.00%
Insider Own 3.36% ROA -25.55% Shares Float 18.16M Beta -1.45
Inst Own 107.45% ROE -44.62% Shares Shorted/Prior 4.66M/3.97M Price 4.79
Gross Margin - Profit Margin - Avg. Volume 103,212 Target Price 72.13
Oper. Margin - Earnings Date Nov 5 Volume 16,248 Change -3.23%
About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics, Inc. News
12/17/24 Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
11/27/24 High Growth Tech Stocks to Watch in November 2024
11/27/24 Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
11/27/24 FDA delays decision of Soleno’s Prader-Willi syndrome drug
11/27/24 Kronos, Idorsia plan layoffs; PTC shelves ALS drug
10:08 AM Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment
08:30 AM Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
11/14/24 Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
11/12/24 Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
11/06/24 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
10/28/24 Soleno Therapeutics to Participate in Upcoming November Investor Conferences
10/25/24 Lamb Weston, Adecoagro, and More Stocks See Action From Activist Investors
10/21/24 Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
10/18/24 TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors
10/16/24 Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR
10/15/24 Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment
10/09/24 SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
10/08/24 Why Soleno Therapeutics Stock Blasted 9% Higher Today
10/08/24 Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
10/03/24 Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc
SLNO Chatroom

User Image seet79 Posted - 32 minutes from now

$SLNO will this be approved end of march?

User Image jacksparo Posted - 3 minutes ago

During my trading journey in 2023 and 2024 some fantastic stocks outperformed from my email alerts! $KULR $SLNO, $ADMA, $RCAT, and $IREN. I am currently searching for more hidden gems for 2025! Stay tuned, my loyal team, for what promises to be a great year of trading in 2025!

User Image Yatejanaif Posted - 5 days ago

$MIRM $SLNO 🔥 MYNZ 86% in 2 days move! FDA fast-track soon Petra’s Hint on X, 88% accuracy (unlike EXAS 42 % \ GH 20%), strong partners (DGX, TMO). $50-$100 target by Q2 2025. 🚀

User Image Quantumup Posted - 1 week ago

Stifel Named $RYTM, $SLNO, and $VERV as its 2025 BioTech Top Picks: $LLY $XBI

User Image MaxwellSteele Posted - 1 week ago

$AKRO $SUPN $SLNO 🔥 MYNZ 🔥 NEWS: Mainz Biomed partners with Quest Diagnostics for a 15,000-patient FDA trial of ColoAlert, targeting U.S. colorectal cancer risk. Partnered w/ Quest (DGX) ($17.3B market cap, $9.25B revenue) for FDA study. Quest gets 18-mo U.S. marketing option for NextGen, distributing to physicians, hospitals, plans, employers & consumers. 🚀 Updated PT: $120 PT (+3,000%) - $440 PT (+12,000%) Recently, $8M to fast-track FDA, TMO co-developing mRNA-based CRC screening. Supporters: P. Starke, G. Starke, F. Muniz. Low float, $50 soon! 🔥

User Image Fraggs_Truffle Posted - 1 week ago

$NRSN $SLNO $IBB $XBI The next SLNO is hidden gem

User Image Fraggs_Truffle Posted - 1 week ago

$NRSN $SLNO Reminds me of when Soleno went from 10 cents to $50.00 on their prader Willi DRUG phase 3 trial win. NRSN has ALS going into phase 3 trial imminenty

User Image Night_Owl_Biotech Posted - 1 week ago

Can anyone familiar with $KALV offer insight into why KALV trades at a low multiple of FY2028 analyst consensus revenue estimates versus its peers? The median FY28 multiple of KALV's FDA approved peers is 2.4 - 2.6 (including those lower we assume due to nearing patent expirations). Last month DRI invested $100MM in exchange for a 5% royalty on Sebetralstat sales ($2B total). KALV is off 13% from a common stock issuance 6 weeks ago. Are analysts wrong or is the TAM too small? Sincere responses appreciated. $SLNO data points are provided $HUMA is off 23% from a financing 4 weeks ago. HUMA's 8/9/24 PDUFA passed without any guidance around the FDA's timeline. Other pre-comm'l bios with PDUFAs did not appear to be good comps $MESO $ATRA This is not investment advice. These 5 stocks generate no revenues & could go bankrupt.

User Image Stocks4thought Posted - 1 week ago

$VOR LSD old- but the jest of it https://www.fredhutch.org/en/news/center-news/2017/06/mylotarg-precision-medicine.html# Among these patients, those who got only chemo had a 49 percent chance of relapsing, but those who also got GO had only a 26 percent risk of relapse. ot $SLNO $VKTX $WVE $QURE

User Image cb28 Posted - 2 weeks ago

$VOR $SLNO $VKTX $BWAY that's a lot of November buys.

User Image Stocks4thought Posted - 2 weeks ago

$VOR Vor was over $40 its in a trash bin--- gonna be a winner- slow train- its like your house fell off a cliff- do you build in the same spot https://whalewisdom.com/stock/vor $$1.17 starts the LP ot $SLNO $VKTX $BWAY

User Image Stocks4thought Posted - 2 weeks ago

$MRKR Sky writing ot $VOR $DRTS $VKTX $SLNO

User Image Stocks4thought Posted - 2 weeks ago

$VOR Ride about to Re-open $SLNO $VKTX $BYRN $CRDF

User Image Stocks4thought Posted - 2 weeks ago

$VOR $PFE mops up- imagine greater Therapuetic window for drugs!@#$T%YUIKL:" ot $SLNO $VKTX $ALT Looking for $1.17 today or .21

User Image Stocks4thought Posted - 2 weeks ago

$VOR ot $DRTS watch video - guy form TX- she will hit $4 soon# ot $SLNO $VKTX $VYGR

User Image thetrackisfast Posted - 3 weeks ago

$SLNO inside

User Image Stocks4thought Posted - 3 weeks ago

$ELDN Very nice- tip $5 and we get $6.5 ot $SLNO $ALT $VKTX $ARWR

User Image Stocks4thought Posted - 3 weeks ago

$TCRX AMAZING GRACE SOON- $nvcr $bwat $itrm $slno $VKTX

User Image Stocks4thought Posted - 3 weeks ago

$CADL Biden pardenomics- $5 shortly ot $SLNO $VKTX $BWAY

User Image monsong Posted - 11/30/24

$CAPR I think our chart will follow suit of $SLNO about to hit that next leg up after initial pop!

User Image Quantumup Posted - 11/29/24

Baird reiterated $SLNO at an Outperform rating and a $72 price target, says it is buyers on weakness from unrelated regulatory outcome: $SLNO shares have traded, directionally, with $APLT shares over the last couple of trading days, as they are both FDA regulatory plays on non-standard applications. Covering both, we think that they really are apples and oranges comparisons and would use the weakness in $SLNO shares as a buying opportunity as we believe approval of DCCR really doesn't require much regulatory flexibility at all, where $APLT was entirely reliant on FDA giving them a pass on the traditional statistical thresholds.

User Image Stocks4thought Posted - 11/29/24

$SGMT $7 soom ot $SLNO $VKTX $ALT $BWAY deeply discounted because of funding event---------not gonna discount- and more commissions for IB's on higher pps. See ya

User Image RoyMunson69 Posted - 11/28/24

$SLNO All the dorkuses are talking about this one because of APLT but who cares either way? Barely any upside here like $GERN

User Image Stocksrunner Posted - 4 weeks ago

Comeback Kings of the Day! 👑These stocks hit rock bottom during the session but roared back to close higher $EVLV $NSPR $SCLX $FCEL $SLNO these kings turned their lowest lows into high-flying closes. Are they setting the stage for tomorrow's rally?

User Image Stocks4thought Posted - 1 month ago

$ARWR ot $DRTS will be soc for inoperable tumors- $SLNO $ALT $#VKTX

User Image TwongStocks Posted - 1 month ago

$SLNO PDUFA extended from Dec 27, 2024 to Mar 25, 2025. "The FDA determined that responses to recent information requests constituted a major amendment to the NDA, resulting in the extension of the PDUFA goal date by three months. The extension allows the FDA time to complete their review, including that of the recently submitted information. The FDA did not cite any safety, efficacy or manufacturing concerns in their correspondence." https://www.globenewswire.com/news-release/2024/11/26/2987503/0/en/Soleno-Therapeutics-Announces-FDA-Extension-of-Review-Period-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome.html

User Image Scanners_Free Posted - 1 month ago

$SLNO NEWS NO GOOOOOOOD

User Image seet79 Posted - 1 month ago

$SLNO odds of approval EOY?

User Image NVDAMillionaire Posted - 1 month ago

$SLNO Soleno Therapeutics (SLNO): Pioneering a Treatment for Prader-Willi Syndrome https://beyondspx.com/article/soleno-therapeutics-slno-pioneering-a-treatment-for-prader-willi-syndrome

User Image Stocks4thought Posted - 1 month ago

$ELDN $4.18 and she stops hooking on the golf course$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ $SLNO $ALT $VKTX

Analyst Ratings
Oppenheimer Outperform Aug 12, 24
Cantor Fitzgerald Overweight Jul 31, 24
Oppenheimer Outperform May 13, 24
Baird Outperform May 10, 24
Piper Sandler Overweight Feb 5, 24
Stifel Buy Jan 23, 24
Oppenheimer Outperform Jan 2, 24
Cantor Fitzgerald Overweight Sep 26, 23
Oppenheimer Outperform Sep 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Yen Kristen SEE REMARKS SEE REMARKS Jan 25 Sell 48.30 397 19,175 25,640 01/29/24
Hirano Patricia C SEE REMARKS SEE REMARKS Jan 25 Sell 48.30 832 40,186 43,142 01/29/24
Anish Bhatnagar CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 25 Sell 48.30 2,527 122,054 171,770 01/29/24
Hirano Patricia C See Remarks See Remarks Dec 13 Sell 37.64 6,244 235,024 19,974 12/15/23
Yen Kristen See Remarks See Remarks Dec 12 Sell 37.14 37,829 1,404,969 2,037 12/14/23
Yen Kristen See Remarks See Remarks Dec 12 Option 2.5 17,916 44,790 19,953 12/14/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Dec 11 Sell 36.09 93,408 3,371,095 24,297 12/13/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Dec 11 Sell 36.24 32,482 1,177,148 12,128 12/13/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Dec 11 Option 2.6 15,000 39,000 44,610 12/13/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Oct 20 Option 2.92 9,643 28,158 198,926 12/13/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Oct 02 Option 2.92 8,309 24,262 41,879 12/13/23
Yen Kristen See Remarks See Remarks Nov 30 Sell 28.6519 3,963 113,547 21,950 12/04/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Nov 30 Sell 28.6519 4,186 119,937 21,303 12/04/23
Hirano Patricia C See Remarks See Remarks Nov 30 Sell 28.6519 3,823 109,536 26,218 12/04/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Nov 30 Sell 28.6519 27,716 794,116 108,062 12/04/23
Yen Kristen See Remarks See Remarks Nov 28 Sell 27.58 7,650 210,987 25,913 11/30/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Nov 28 Sell 27.58 8,081 222,874 25,489 11/30/23
Hirano Patricia C See Remarks See Remarks Nov 28 Sell 27.58 7,381 203,568 30,041 11/30/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Nov 28 Sell 27.58 53,505 1,475,668 135,778 11/30/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Sep 26 Buy 14.76 866,789 12,793,806 3,074,542 09/28/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner May 24 Buy 5.31 85,000 451,350 2,029,455 05/26/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner May 19 Buy 5.06 80,000 404,800 1,944,455 05/23/23
SCHULER JACK W 10% Owner 10% Owner Aug 02 Sell 2.64 180,523 476,581 466,666 10/14/22
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Jan 21 Sell 0.373 39,033 14,559 370,227 01/25/22